AstraZeneca PLC

Alpha Score of 49 reflects weak overall profile with moderate momentum, poor value, strong quality, moderate sentiment.

AstraZeneca PLC American Depositary Shares represent ownership in AstraZeneca PLC, a multinational biopharmaceutical company headquartered in Cambridge, United Kingdom. The company focuses on the discovery, development, manufacture, and commercialization of prescription medicines across key therapeutic areas. Oncology constitutes its largest segment, featuring products like Tagrisso, Imfinzi, Calquence, Enhertu, and Truqap. Other core areas include cardiovascular, renal, and metabolic medicines such as Farxiga and Brilinta; rare disease therapies like Ultomiris and Soliris; and respiratory and immunology treatments including Symbicort, Fasenra, and Breztri. AstraZeneca PLC also offers vaccines and immune therapies. It serves primary and specialty care physicians globally through distributors and local offices, with significant presence in the United States, Europe, and Asia. This structure positions AstraZeneca PLC as a major player in the global pharmaceutical industry, addressing diverse medical needs in oncology, rare diseases, and chronic conditions.